LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Fermé

2.33 -20.48

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.33

Max

2.33

Chiffres clés

By Trading Economics

Revenu

44M

-26M

Ventes

-5.8M

42M

Marge bénéficiaire

-61.388

Employés

550

EBITDA

44M

-22M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+45.16% upside

Dividendes

By Dow Jones

Prochains Résultats

25 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

8.3M

1.1B

Ouverture précédente

22.81

Clôture précédente

2.33

Score Technique

By Trading Central

Confiance

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

22 févr. 2026, 23:55 UTC

Market Talk

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22 févr. 2026, 23:53 UTC

Market Talk

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22 févr. 2026, 23:53 UTC

Market Talk

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22 févr. 2026, 23:51 UTC

Market Talk

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22 févr. 2026, 23:35 UTC

Market Talk

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22 févr. 2026, 23:21 UTC

Résultats

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22 févr. 2026, 23:20 UTC

Résultats

Nickel Industries 2025 Operating Profit US$126.4 Million

22 févr. 2026, 23:19 UTC

Résultats

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22 févr. 2026, 23:19 UTC

Résultats

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22 févr. 2026, 23:18 UTC

Résultats

Nickel Industries Won't Pay a Final Dividend

22 févr. 2026, 23:16 UTC

Résultats

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22 févr. 2026, 21:35 UTC

Résultats

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22 févr. 2026, 21:34 UTC

Résultats

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22 févr. 2026, 21:34 UTC

Résultats

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22 févr. 2026, 21:33 UTC

Résultats

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22 févr. 2026, 21:33 UTC

Résultats

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22 févr. 2026, 21:28 UTC

Résultats

Ampol Final Dividend A$0.60/Share

22 févr. 2026, 21:28 UTC

Résultats

Ampol FY Revenue A$31.37 Billion, Down 10%

22 févr. 2026, 21:28 UTC

Résultats

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22 févr. 2026, 21:28 UTC

Résultats

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21 févr. 2026, 14:31 UTC

Acquisitions, Fusions, Rachats

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21 févr. 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

20 févr. 2026, 23:12 UTC

Acquisitions, Fusions, Rachats

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 févr. 2026, 22:12 UTC

Résultats

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 févr. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20 févr. 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20 févr. 2026, 21:23 UTC

Résultats

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 févr. 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 févr. 2026, 21:01 UTC

Acquisitions, Fusions, Rachats

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 févr. 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

45.16% hausse

Prévisions sur 12 Mois

Moyen 4.5 USD  45.16%

Haut 4.5 USD

Bas 4.5 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

2

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

2.02 / 2.115Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat